Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: A randomized clinical trial

Diabetes Care

Volumn 40, Issue 5, 2017, Pages 632-639

  Hollander, Priscilla ^a   Bays, Harold E ^b   Rosenstock, Julio ^c   Frustaci, Mary Ellen ^d   Fung, Albert ^e   Vercruysse, Frank ^d   Erondu, Ngozi ^e  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^c Dallas Diabetes and Endocrine Center at Medical City   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; PHENTERMINE; PLACEBO; ANOREXIGENIC AGENT; ANTIDIABETIC AGENT; THIOPHENE DERIVATIVE;

ADULT; AGED; ANXIETY DISORDER; BODY WEIGHT MANAGEMENT; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MONOTHERAPY; MULTICENTER STUDY; MYCOSIS; OBESITY; OUTCOME ASSESSMENT; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; URINARY TRACT INFECTION; WEIGHT CHANGE; WEIGHT REDUCTION; BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERWEIGHT; PATHOPHYSIOLOGY;

ADULT; APPETITE DEPRESSANTS; BLOOD PRESSURE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PHENTERMINE; THIOPHENES;

EID: 85019391775     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-2427     Document Type: Conference Paper

References (34)

1. American Medical Association House of Delegates. Resolution 420 (A-13). Recognition of obesity as a disease [Internet], 2013. Available from http://www.ama-assn.org/assets/meeting/2013a/a13-addendum-refcomm-d.pdf. Accessed 14 November 2016
2. Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol 2013;7:304-383
3. Klein S, Burke LE, Bray GA, et al.; American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952-2967
4. Jensen MD, Ryan DH, Apovian CM, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014;129(Suppl. 2):S102-S138
5. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes 2005;29:1153-1167
6. U. S. Food and Drug Administration. Guidance for industry: developing products for weight management [Internet], 2007. Available from http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071612.pdf. Accessed 14 November 2016
7. Allison DB, Gadde KM, Garvey WT, et al. Controlledrelease phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-342
8. Garvey WT, Ryan DH, Look M, et al. Twoyear sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297-308
9. Apovian CM, Aronne LJ, Bessesen DH, et al.; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100:342-362
10. Garvey WT, Ryan DH, Bohannon NJ, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 2014;37:3309-3316
11. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-672
12. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-545
13. Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014;22:1042-1049
14. Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann NYAcad Sci 2015;1358:28-43
15. Meininger G, Canovatchel W, Polidori D, Rosenthal N. Canagliflozin for the treatment of adults with type 2 diabetes. Diabetes Manag 2015;5:183-201
16. Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014;2:691-700
17. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-2022
18. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodiumglucose cotransporter 2 inhibition. Diabetes Care 2015;38:1730-1735
19. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011;60:890-898
20. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 2012;20:1645-1652
21. Polidori D, Sanghvi A, Seeley R, Hall KD. How strongly does appetite counter weight loss? Quantification of the homeostatic control of human energy intake. Obesity (Silver Spring) 2016;24:2289-2295
22. BELVIQ (lorcaserin hydrochloride) tablets, for oral use [package insert]. Woodcliff Lake, NJ, Eisai, Inc., 2012
23. CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets [package insert]. Deerfield, IL, Takeda Pharmaceuticals America, Inc., 2014
24. QSYMIA (phentermine and topiramate extended-release) capsules, for oral use, CIV [package insert]. Mountain View, CA, VIVUS, Inc., 2014
25. SAXENDA (liraglutide [rDNA origin] injection), solution for subcutaneous use [package insert]. Plainsboro, NJ, Novo Nordisk, 2016
26. Kusti M, Olgers F, Akkary E. Pharmacological approach for obesity. In Anti-Obesity Drug Discovery and Development. Atta-ur-Rahman, Iqbal Choudhary M, Eds. Sharjah, United Arab Emirates, Bentham Science Publishers Ltd., 2011, p. 67-81
27. Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab 2015;17:1021-1032
28. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-1352
29. Pi-Sunyer X, Astrup A, Fujioka K, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22
30. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring) 2013;21:2163-2171
31. Hall KD, Sacks G, Chandramohan D, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet 2011;378:826-837
32. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU):52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-950
33. Toubro S, Cefalu WT, Xie J, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes (Abstract). Diabetologia 2012;55:S313-S314
34. Blonde L, Stenlöf K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med 2016;128:371-380